AbbVie, Amgen, and Takeda collaborate using clinical trial data and real-world evidence (RWE) to combat COVID-19
- The partner companies will evaluate the ability of the drugs to reduce or mitigate the severity of acute respiratory distress syndrome (ARDS), which is observed in around 10-15% of COVID-19 patients
- As part of the alliance, members are sharing clinical trial data and RWE, as well as crowd-sourcing early-stage candidates to identify mechanisms or treatments that could be effective against COVID-19
- The joint trial is just the latest in a growing trend of pharmaceutical companies repurposing existing drugs and experimental candidates as potential treatments for COVID-19
Click here to learn more
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.